HealthyNCT06329063
Oral Vasopressin Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study
A study testing Vasopressin in people with Healthy, run by University of Electronic Science and Technology of China at 1 site in China.
Trial summary
The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on the perception of time-to-collision of threatening and non-threatening stimuli by combining a validated looming fear eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological… Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Vasopressin
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteChina
- Study dates
- 5 Mar 2024to 30 Jul 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent.
- Normal or corrected-normal version
Who cannot join
- History of neuropsychiatric diseases.
- History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness.
- History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction.
- History of renal diseases, including renal stones or renal failure.
- History of hyponatremia(Serum sodium <135mmol/L) or hyperkalemia (Serum potassium>5.5mmol/L); history of diabetes mellitus or diabetes insipidus
- Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food.
Show all 9Show fewer
- Infections such as COVID-19 or influenza, or unexplained fever.
- Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg).
- History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3 pipes/day); smoker using e-cigarettes.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
University of Electronic Science and Technology of China
Chengdu, Sichuan
Weihua Zhao, Dr, 86-28-61830811, zarazhao.uestc@outlook.com
About this study
Official title: Vasopressin Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study
The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on the perception of time-to-collision of threatening and non-threatening stimuli by combining a validated looming fear eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.
Read the detailed description
Animal models and initial findings in humans suggest a role of the AVP signaling system in socio-emotional processes. At the same time, the visual system's remarkable ability to perceive and interpret impending threats, notably through the "looming" phenomenon- a distinct pattern of optical expansion on the retina as objects approach, theoretically allows for precise estimation of the time-to-collision (TTC). It was recently demonstrated that the affective content of looming stimuli influences perceived TTC, with threatening objects judged as approaching sooner than non-threatening objects, hinting at a nuanced interaction between emotional valence and temporal perception. Within this context the present study aims to validate the effects of orally administered on the perception of time-to-collision of threatening and non-threatening stimuli. To this end, healthy individuals will undergo a double-blind, between-subjects, placebo-controlled pharmaco-eye-tracking experiment and receive a single oral dose of vasopressin (20 IU) or placebo before performing a looming visual stimuli task 45 minutes after administration. The task paradigm will encompass threatening (butterfly, rabbit) and non-threatening (spider, snake) stimuli
- Conditions
- Healthy
- Being tested
- Vasopressin, Placebo
- Keywords
- Eye-tracking, vasopressin, looming fear
- Medical subject headings
- Diabetes Insipidus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VasopressinDrug
Also called Antidiuretic Hormone
Administration of vasopressin (20 IU) (oral spray)
PlaceboDrug
Also called Placebo treatment
Administration of placebo (oral spray)
| Study group | Role | What they receive |
|---|---|---|
| Vasopressin group | Experimental | Drug: Vasopressin (20IU) Receives: Drug: Vasopressin |
| Placebo group | Placebo comparator | Drug: Placebo Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Ratio of judged-time-to-collision to actual-time-to-collision for threatening versus non-threatening stimuli after oral vasopressin administration
Comparison of the ratio between the judged time to collision and the actual time to collision between the treatment groups for threatening (spider, snake) and non-threatening (rabbit, butterfly) stimuli.
Measured: 75 minutes - 105 minutes after treatment
Secondary outcomes (2)
First saccade latency(ms) for threatening versus non-threatening stimuli after oral vasopressin administration
Comparison of first saccade latencies between treatment groups for threatening (spider, snake) and non-threatening (rabbit, butterfly) stimuli.
Measured: 75 minutes - 105 minutes after treatment
Fixation duration(ms) for threatening versus non-threatening stimuli after oral vasopressin administration
Comparison of mean fixation durations between treatment groups for threatening (spider, snake) and non-threatening (rabbit, butterfly) stimuli.
Measured: 75 minutes - 105 minutes after treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Mar 2024
- Study start5 Mar 2024
- Primary completion1 Jun 2025 (estimated)
- Study completion30 Jul 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Electronic Science and Technology of China
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Benjamin Becker, University of Electronic Science and Technology of China
- Investigators
- Benjamin Becker, Dr, Principal investigator, University of Electronic Science and Technology of China
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06329063
- Sponsor's protocol ID
- BAM_lab_eyetracking_03
- Status last verified
- Apr 2024
- First submitted
- 15 Mar 2024
- Last updated
- 11 Apr 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Han M, Dong W, Fu K, Wang J, Xu Y, Zheng Y, Kendrick K, Ferraro S, Xu T, Yao D, Becker B. Vasopressin and angiotensin II pathways differentially modulate human fear response dynamics to looming threats. PLoS Biol. 2026 Feb 24;24(2):e3003668. doi: 10.1371/journal.pbio.3003668. eCollection 2026 Feb.
PubMed 41734211
Study at a glance
From the registry record, last updated by the sponsor on 11 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vasopressin Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study
- ClinicalTrials.gov ID
- NCT06329063
- Acronym / sponsor ID
- BAM_lab_eyetracking_03
- Conditions
- Healthy
- Keywords
- Eye-tracking, vasopressin, looming fear
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- University of Electronic Science and Technology of ChinaUniversity, hospital or other
- Study start
- 5 Mar 2024 (actual)
- Primary completion
- 1 Jun 2025 (estimated)
- Study completion
- 30 Jul 2025 (estimated)
- First posted
- 25 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on the perception of time-to-collision of threatening and non-threatening stimuli by combining a validated looming fear eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.
Detailed description
Animal models and initial findings in humans suggest a role of the AVP signaling system in socio-emotional processes. At the same time, the visual system's remarkable ability to perceive and interpret impending threats, notably through the "looming" phenomenon- a distinct pattern of optical expansion on the retina as objects approach, theoretically allows for precise estimation of the time-to-collision (TTC). It was recently demonstrated that the affective content of looming stimuli influences perceived TTC, with threatening objects judged as approaching sooner than non-threatening objects, hinting at a nuanced interaction between emotional valence and temporal perception. Within this context the present study aims to validate the effects of orally administered on the perception of time-to-collision of threatening and non-threatening stimuli. To this end, healthy individuals will undergo a double-blind, between-subjects, placebo-controlled pharmaco-eye-tracking experiment and receive a single oral dose of vasopressin (20 IU) or placebo before performing a looming visual stimuli task 45 minutes after administration. The task paradigm will encompass threatening (butterfly, rabbit) and non-threatening (spider, snake) stimuli
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Vasopressin group | Experimental | Drug: VasopressinDrug: Vasopressin (20IU) |
| Placebo group | Placebo comparator | Drug: PlaceboDrug: Placebo |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent.
- Normal or corrected-normal version
Key exclusion criteria (9 listed)
- History of neuropsychiatric diseases.
- History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness.
- History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction.
- History of renal diseases, including renal stones or renal failure.
- History of hyponatremia(Serum sodium <135mmol/L) or hyperkalemia (Serum potassium>5.5mmol/L); history of diabetes mellitus or diabetes insipidus
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VasopressinAlso: Antidiuretic HormoneAdministration of vasopressin (20 IU) (oral spray) | Drug | Vasopressin group |
| PlaceboAlso: Placebo treatmentAdministration of placebo (oral spray) | Drug | Placebo group |
Primary outcome
Ratio of judged-time-to-collision to actual-time-to-collision for threatening versus non-threatening stimuli after oral vasopressin administration
Time frame: 75 minutes - 105 minutes after treatment
Comparison of the ratio between the judged time to collision and the actual time to collision between the treatment groups for threatening (spider, snake) and non-threatening (rabbit, butterfly) stimuli.
2 secondary outcomes
First saccade latency(ms) for threatening versus non-threatening stimuli after oral vasopressin administration
Time frame: 75 minutes - 105 minutes after treatment
Fixation duration(ms) for threatening versus non-threatening stimuli after oral vasopressin administration
Time frame: 75 minutes - 105 minutes after treatment
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Apr 2024.
- Derived from this study: PubMed 41734211Han M, Dong W, Fu K, Wang J, Xu Y, Zheng Y, Kendrick K, Ferraro S, Xu T, Yao D, Becker B. Vasopressin and angiotensin II pathways differentially modulate human fear response dynamics to looming threats. PLoS Biol. 2026 Feb 24;24(2):e3003668. doi: 10.1371/journal.pbio.3003668. eCollection 2026 Feb.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Benjamin Becker, Dr principal investigator
University of Electronic Science and Technology of China
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Vasopressin in people with Healthy, run by University of Electronic Science and Technology of China at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 11 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Weihua Zhao, Dr (86-28-61830811, zarazhao.uestc@outlook.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Ratio of judged-time-to-collision to actual-time-to-collision for threatening versus non-threatening stimuli after oral vasopressin administration (time frame: 75 minutes - 105 minutes after treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06329063, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Apr 2024.